Abstracts tagged "Diagnostic criteria and spondylarthritis"

Abstract Number: 2505 • 2017 ACR/ARHP Annual Meeting
Trends in Time to Diagnosis in Spondyloarthritis Patients. Association with 2009 ASAS Classification Criteria and Clinical Presentation at Disease Onset. Data from Comospa Study
Rodolfo Perez-Alamino¹, Hernán Maldonado Ficco², Christian A. Waimann³, José Antonio Maldonado-Cocco^4,5, Anna Moltó⁶, Maxime Dougados⁷, Désirée van der Heijde⁸, Robert B.M. Landewé⁹ and Filip van Den Bosch¹⁰, ¹Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, ²section of Rheumatology, Clinica Regional del Sud, Córdoba, Argentina, Córdoba, Argentina, ³Hospital Dr. Hector Cura, Olavarria, Argentina, ⁴Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ⁵Fundación Reumatológica Argentina, Buenos Aires, Argentina, ⁶Hôpital Cochin, AP-HP, Paris, France, ⁷Paris, Paris, France, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Academic Medical Center, Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ¹⁰Rheumatology, Ghent University Hospital, Gent, Belgium
Background/Purpose: Diagnostic delay is one of the greatest challenges in Spondyloarthritis (SpA). Methods: We designed a cross-sectional study, including adult patients fulfilling ASAS SpA criteria…
Abstract Number: 2606 • 2014 ACR/ARHP Annual Meeting
How to Classify Spondyloarthritis after a Two Year Follow up? Results from the French Recent onset spondyloarthritis Cohort
Pierre Gazeau¹, Divi Cornec², Marie Agnès Timsit¹, Valerie Devauchelle³, Sandrine Jousse-Joulin¹, Thierry Marhadour⁴, Emmanuel Nowak⁵, Maxime Dougados⁶ and Alain Saraux⁷, ¹Rheumatology, CHU Brest, Brest, France, ²Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, ³Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ⁴Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁵CIC, CHU Brest, Brest, France, ⁶INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁷Rhumatologie, CHU Brest and EA 2216, UBO, Brest, France
Background/Purpose: In early arthritis, after a two years follow up, rheumatologist diagnosis of rheumatoid arthritis agrees well with 2010 ACR/EULAR criteria (Saraux A et al.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].